Loading...
Loading...
Browse all stories on DeepNewz
VisitEMA Recommends Leqembi for Early Alzheimer's in Patients with ApoE4 Gene; Biogen Shares Rise 5%
Nov 14, 2024, 04:16 PM
The European Medicines Agency (EMA) has recommended the approval of Leqembi, a drug developed by Eisai and Biogen, for the treatment of early Alzheimer's disease. This decision comes after the agency initially rejected the treatment months prior. The recommendation was made by the Committee for Medicinal Products for Human Use (CHMP) and pertains specifically to patients with one or no copies of the ApoE4 gene. The drug has been shown to slow cognitive decline in these patients. Following the announcement, Biogen's shares rose by as much as 5%. The final verdict from the European Commission is still pending.
View original story
Markets
No • 50%
Yes • 50%
Biogen stock price data from financial markets
No • 50%
Yes • 50%
Official announcements from major international regulatory bodies
Yes • 50%
No • 50%
Official announcement from the European Commission
Decrease by 0% to 5% • 25%
Decrease by more than 5% • 25%
Increase by more than 5% • 25%
Increase by 0% to 5% • 25%
Biogen stock price data from financial markets
Low (1%-10% of target market) • 25%
High (>20% of target market) • 25%
Negligible (<1% of target market) • 25%
Moderate (10%-20% of target market) • 25%
Market reports and sales data from Biogen and Eisai
Decision delayed • 25%
Approved without restrictions • 25%
Approved with restrictions • 25%
Rejected • 25%
Official announcement from the European Commission